AR073072A1 - Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano - Google Patents

Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano

Info

Publication number
AR073072A1
AR073072A1 ARP090103163A ARP090103163A AR073072A1 AR 073072 A1 AR073072 A1 AR 073072A1 AR P090103163 A ARP090103163 A AR P090103163A AR P090103163 A ARP090103163 A AR P090103163A AR 073072 A1 AR073072 A1 AR 073072A1
Authority
AR
Argentina
Prior art keywords
rankl
human
binding
antibodies
human antibodies
Prior art date
Application number
ARP090103163A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41350749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR073072A1 publication Critical patent/AR073072A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos humanos aislados o sus fragmentos de union a antígenos, que se unen específicamente a RANKL humano y bloquean la union de hRANKL a un receptor de RANK. Los anticuerpos son utiles para prevenir o tratar trastornos y/o enfermedades, que están asociados con las interacciones RANKL/RANK, incluyendo trastornos oseos o cáncer. Molécula de ácido nucleico que lo codifica, vector y composicion farmacéutica.
ARP090103163A 2008-08-19 2009-08-18 Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano AR073072A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8991808P 2008-08-19 2008-08-19
US16058809P 2009-03-16 2009-03-16

Publications (1)

Publication Number Publication Date
AR073072A1 true AR073072A1 (es) 2010-10-13

Family

ID=41350749

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103163A AR073072A1 (es) 2008-08-19 2009-08-18 Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano

Country Status (6)

Country Link
US (1) US8414890B2 (es)
AR (1) AR073072A1 (es)
CL (1) CL2009001735A1 (es)
TW (1) TW201019959A (es)
UY (1) UY32061A (es)
WO (1) WO2010022120A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
WO2011116527A1 (en) * 2010-03-26 2011-09-29 Qing Fa Liu Anti human rankl monoclonal antibodies and uses thereof
BR112012032185A2 (pt) * 2010-06-17 2016-10-11 Trellis Bioscience Inc anticorpos úteis na imunização passiva de influenza.
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
ES2607086T3 (es) 2010-11-10 2017-03-29 F. Hoffmann-La Roche Ag Métodos y composiciones para la inmunoterapia de enfermedades neuronales
EP2692359B1 (en) * 2011-03-31 2017-06-07 Oriental Yeast Co., Ltd. Cancer immunopotienting agent containing rankl antagonist
JP6371222B2 (ja) 2011-12-05 2018-08-08 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザの受動免疫用抗体
WO2013176469A1 (ko) * 2012-05-21 2013-11-28 이화여자대학교 산학협력단 파골세포분화를 억제할 수 있는 항체
CA2906676A1 (en) 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
MX2016010059A (es) 2014-02-04 2017-04-27 Contrafect Corp Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
WO2016075221A1 (en) * 2014-11-14 2016-05-19 Probiocon Gmbh Rankl-specific agent for treating metastatic disease
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
CN109890845B (zh) * 2016-10-28 2022-07-01 伊莱利利公司 抗rankl抗体及其用途
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
EP3661558A4 (en) 2017-08-01 2021-08-11 City of Hope ANTI-IL1RAP ANTIBODIES
KR20210032488A (ko) * 2018-07-20 2021-03-24 서피스 온콜로지, 인크. 항-cd112r 조성물 및 방법
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
CN117285637B (zh) * 2023-11-22 2024-03-22 江苏迈威康新药研发有限公司 一种抗独特型抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
MXPA04009681A (es) * 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species

Also Published As

Publication number Publication date
WO2010022120A1 (en) 2010-02-25
US20120114665A1 (en) 2012-05-10
TW201019959A (en) 2010-06-01
US8414890B2 (en) 2013-04-09
UY32061A (es) 2010-03-26
CL2009001735A1 (es) 2010-02-19

Similar Documents

Publication Publication Date Title
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CY1122399T1 (el) Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
AR069681A1 (es) Moleculas de union al receptor ox40 humano
NZ761294A (en) Binding agents binding to pd-l1 and cd137 and use thereof
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
BR112013028779A2 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, método para tratar um paciente humano afligido com um distúrbio ou doença inflamatórios, e, uso de uma composição
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
UY29653A1 (es) Nuevos anticuerpos anti-madcam
PE20151180A1 (es) Anticuerpos anti-ceacam5 y usos de estos
CL2013001468A1 (es) Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
BR112013021460A2 (pt) molécula de ligação ao antígeno variante, anticorpos isolado e que se liga ao antígeno carcinoembrionário humano, polinucleotídeo isolado, vetor, célula hospedeira, composição, métodos para induzir a lise celular de uma célula tumoral, de tratamento de um sujeito possuindo um câncer e para aumentar o tempo de sobrevida e uso
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure